Chart - CYP, page-294

I have no doubt the that both companies cells work, MSB is well ahead in getting to market, but you do ask a valid question. To further that question, it would be great to know from both companies; what is the quantity of cells you can make in those timeframes currently? Ie, how many doses can MSB actually produce or have immediately available if overwhelming efficacy is shown in their COVId trial? Having a great treatment means nothing if you can only treat a few hundred patients.....
I have not read anywhere about the actual number of doses they can immediately produce.... it’s all talk of new 3D bioreactors, manufacturing partners etc.... but where is the specific data? Wild revenue numbers sound amazing and could be true if only the cells can be produced.